Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma

被引:9
作者
Chen, Chien-Hsu [1 ,2 ,3 ,4 ]
Tsai, Mu-Yao [1 ,2 ]
Chiang, Ping-Chia [1 ,2 ]
Sung, Ming-Tse [2 ,5 ]
Luo, Hao-Lun [1 ,2 ]
Suen, Jau-Ling [3 ]
Tsai, Eing-Mei [3 ,6 ,7 ]
Chiang, Po-Hui [1 ,2 ,8 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Urol, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
[2] Chang Gung Univ, Coll Med, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
[3] Kaohsiung Med Univ, Coll Med, Grad Inst Med, 100 Shih Chuan 1st Rd, Kaohsiung 80708, Taiwan
[4] Shu Univ, Coll Liberal Educ, Div Nat Sci, Kaohsiung, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan
[6] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ, Ctr Excellence Environm Med, Grad Inst Med, Kaohsiung, Taiwan
[8] Kaohsiung Med Univ, Coll Med, Kaohsiung, Taiwan
关键词
Combined positive score; Immune checkpoint inhibitor; Programmed death-ligand 1; Survival; Upper tract urothelial carcinoma;
D O I
10.1007/s00262-021-02890-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Upper tract urothelial carcinoma (UTUC) is relatively rare in Western countries. The impact of programmed death-ligand 1 (PD-L1) expression on UTUC remains unclear because previous studies have focused on bladder UC. We investigated the association of PD-L1 expression with clinicopathological features and prognosis in patients with UTUC. Methods We retrospectively reviewed the patients with UTUC that we treated at our institute from 2013 to 2018. In total, 105 patients with UTUC undergoing radical nephroureterectomy were analyzed to evaluate the PD-L1 expression on representative whole-tissue sections using the Combined Positive Score (CPS; Dako 22C3 pharmDx assay). A PD-L1 CPS >= 10 was considered positive. Results Among the 105 UTUC cases, 17.1% exhibited positive PD-L1 expression. A CPS >= 10 was significantly associated with higher tumor stage (>= T2, p = 0.034) and lymph node invasion at diagnosis (p = 0.021). A multivariable analysis indicated that a CPS >= 10 was an independent prognostic predictor of shorter cancer-specific survival (hazard ratio [HR] = 4.59, 95% confidence interval [CI] = 1.66 - 12.7, p = 0.003) and overall survival (HR = 2.51, 95% CI = 1.19 - 5.27, p = 0.015). Conclusions A PD-L1 CPS >= 10 in UTUC was associated with adverse pathological features and independently predicted worse cancer-specific and overall survival.
引用
收藏
页码:2981 / 2990
页数:10
相关论文
共 33 条
  • [1] Arriola AGP, 2019, AM J CLIN PATHOL, V151, P561, DOI [10.1093/AJCP/AQZ002, 10.1093/ajcp/aqz002]
  • [2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    [J]. LANCET ONCOLOGY, 2017, 18 (11) : 1483 - 1492
  • [3] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [4] Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
    Bellmunt, J.
    Mullane, S. A.
    Werner, L.
    Fay, A. P.
    Callea, M.
    Leow, J. J.
    Taplin, M. E.
    Choueiri, T. K.
    Hodi, F. S.
    Freeman, G. J.
    Signoretti, S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (04) : 812 - 817
  • [5] T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival
    Boorjian, Stephen A.
    Sheinin, Yuri
    Crispen, Paul L.
    Farmer, Sara A.
    Lohse, Christine M.
    Kuntz, Susan M.
    Leibovich, Bradley C.
    Kwon, Eugene D.
    Frank, Igor
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (15) : 4800 - 4808
  • [6] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Chen, Daniel S.
    Irving, Bryan A.
    Hodi, F. Stephen
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6580 - 6587
  • [7] The PD-1/PD-Ls pathway and autoimmune diseases
    Dai, Suya
    Jia, Ru
    Zhang, Xiao
    Fang, Qiwen
    Huang, Lijuan
    [J]. CELLULAR IMMUNOLOGY, 2014, 290 (01) : 72 - 79
  • [8] Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
    Ding, Xiangli
    Chen, Qiaochao
    Yang, Zhao
    Li, Jun
    Zhan, Hui
    Lu, Nihong
    Chen, Min
    Yang, Yanlong
    Wang, Jiansong
    Yang, Delin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4171 - 4184
  • [9] Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+T Cells in Urothelial Carcinoma
    Faraj, Sheila F.
    Munari, Enrico
    Guner, Gunes
    Taube, Janis
    Anders, Robert
    Hicks, Jessica
    Meeker, Alan
    Schoenberg, Mark
    Bivalacqua, Trinity
    Drake, Charles
    Netto, George J.
    [J]. UROLOGY, 2015, 85 (03) : 703.e1 - 703.e6
  • [10] Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma
    Foerster, Beat
    Abufaraj, Mohammad
    Petros, Firas
    Azizi, Mounsif
    Gupta, Mohit
    Schweitzer, Donald
    Margulis, Vitaly
    Iwata, Takehiro
    Kimura, Shoji
    Shabsigh, Ahmad
    Briganti, Alberto
    Ku, Ja H.
    Muilwijk, Tim
    Kassouf, Wassim
    Matin, Surena F.
    Spiess, Philippe E.
    Pierorazio, Phillip M.
    Hendricksen, Kees
    Shariat, Shahrokh F.
    [J]. JOURNAL OF UROLOGY, 2020, 203 (06) : 1101 - 1108